December 2017 Briefing – Nephrology
Here are what the editors at HealthDay consider to be the most important developments in Nephrology for December 2017. This roundup includes the latest...
Out-of-Pocket Costs Correlate With Receipt of Cancer Care
Across cancers, higher costs tied to higher rates of oral prescription abandonment, delayed initiation
Risk of ESRD in T1DM Patients Has Fallen Markedly in Finland
Relative risk of end-stage renal disease was 0.13 in those diagnosed in 1995-2011 versus 1965-1979
Rituximab Effective for Lupus-Associated Cytopenia
Overall initial response rate of 86 percent in 71 patients, with complete response for 60.5 percent
CDC: 2015 to 2016 Saw Drop in Life Expectancy in United States
Increase in rate of age-adjusted drug overdose deaths observed during same time period
Early-Stage Cancer Diagnoses Up With ACA’s Medicaid Expansions
Both overall and early diagnosis of cancer increased in first year of expansions
Year One Results Out for Value-Based Payment Modifier Program
Overall, 29.3 percent of eligible practices failed to register and report data and received a penalty
Expanded TIMI Risk Score Deemed Practical in Diabetes
Atherothrombotic disease risk assessment based upon 10 readily available clinical variables
Recent Decrease in Excess Risk of All-Cause Mortality in ESRD
Decrease in excess risk of all-cause mortality from 1995 to 2013 for those with end-stage renal disease
Recent Change in Spectrum of HIV-Linked Kidney Disease
Improvement of therapy for HIV infection has changed incidence, type, severity of kidney diseases
